FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895924817> ?p ?o ?g. }

• W2895924817 endingPage "S220" @default.
• W2895924817 startingPage "S220" @default.
• W2895924817 abstract "The international study on MRI-guided Brachytherapy in locally Advanced Cervical cancer (EMBRACE, www.embracestudy.dk) is a prospective observational study of treatment and clinical outcome data of 1416 patients with locally advanced cervical cancer from 23 centers, who were treated with radiochemotherapy (EBRT and image-guided brachytherapy (IGBT), between 2008 and 2016. EMBRACE data reflect the implementation of MRI-based IGBT through a variety of institutional protocols. The aim of this analysis was to report on the overall status of the implementation of this technique and to analyze dose-volume parameters according to GEC ESTRO recommendations. There were 1300 patients with complete treatment data records were included in this analysis. The distribution of implant types (intracavitary [ic] or intracavitary/interstitial [ic/is]), and dose rate schedules (high/pulsed dose rate [HDR/PDR]) was analyzed. Total treatment doses including EBRT and IGBT were converted to biologically equieffective dose in 2Gy fractions (EQD2) using the linear quadratic model, and dose reporting parameters for high-risk CTV (CTVHR) and organs at risk according to ICRU89 and GEC-ESTRO recommendations. A subgroup analysis was performed for different target volumes. Almost all patients were treated with EBRT of 45-50.4 Gy to the elective PTV, with 3D conformal (58%) or IMRT (42%) techniques. HDR BT (57%) was delivered mostly in 3 (20%), 4 (73%) or 5 (7%) fractions; PDR BT (42%) in 1 or 2 fractions (50%/50%). Most BT treatments were delivered with ring applicators (58%), followed by ovoids (27%), vaginal molds (12%) or cylinders (1%). IC applicators were exclusively used in 56% of patients, 44% were treated with ic/is only, or a combination of techniques. In ic/is implants the mean number of active needles per patient was 4.1±2.8. The mean overall treatment time for EBRT (including any sequential nodal boosts) and BT was 46.5±6.5 days. BT was administered after delivery of at least 45Gy of EBRT in 58% of patients, while 39% of BT treatments started after 30-45 Gy EBRT. The FIGO stage distribution was 19% 1B, 5% 2A, 52% 2B, 1% 3A, 15% 3B, 3% 4A, and 5% 4B. The median CTVHR volume was 28.7 cm3 (mean 34.5±21.5 cm3). The mean CTVHR D90 was 89.7±8.8 Gy EQD210. For ic treatments, the mean point A dose was 74.1±7.6 Gy EQD210. For ic and ic/is groups, with mean CTVHR volumes of 26.5 and 44.8 cm3, the mean CTVHR D90 were 90.5/88.7 Gy EQD210. Overall, for CTVHR volumes </> 30cm3, the mean D90 was 92.5/86.5 Gy EQD210, mean D2cm3 was 73.8/79.4 for bladder, and 61.1/64.3 Gy EQD23 for rectum. In total 76% of all patients received a CTVHR D90>85 Gy EQD210, 92% had a bladder D2cm3 <90 Gy EQD3, and 95% had a rectum D2cm3 <75Gy EQD3. The prospective EMBRACEII protocol will further promote the implementation of IGBT with ic/is technique. Further improvement of target coverage and organ sparing is expected." @default.
• W2895924817 created "2018-10-26" @default.
• W2895924817 creator A5010078716 @default.
• W2895924817 creator A5021919710 @default.
• W2895924817 creator A5022443896 @default.
• W2895924817 creator A5024328926 @default.
• W2895924817 creator A5042729624 @default.
• W2895924817 creator A5053709216 @default.
• W2895924817 creator A5065451656 @default.
• W2895924817 creator A5071171991 @default.
• W2895924817 creator A5072760427 @default.
• W2895924817 creator A5077820862 @default.
• W2895924817 creator A5085510763 @default.
• W2895924817 creator A5085569334 @default.
• W2895924817 date "2018-11-01" @default.
• W2895924817 modified "2023-09-25" @default.
• W2895924817 title "Dose and Volume Parameters for MRI-Guided Cervix Cancer Brachytherapy in the Embrace Trial" @default.
• W2895924817 doi "https://doi.org/10.1016/j.ijrobp.2018.07.142" @default.
• W2895924817 hasPublicationYear "2018" @default.
• W2895924817 type Work @default.
• W2895924817 sameAs 2895924817 @default.
• W2895924817 citedByCount "0" @default.
• W2895924817 crossrefType "journal-article" @default.
• W2895924817 hasAuthorship W2895924817A5010078716 @default.
• W2895924817 hasAuthorship W2895924817A5021919710 @default.
• W2895924817 hasAuthorship W2895924817A5022443896 @default.
• W2895924817 hasAuthorship W2895924817A5024328926 @default.
• W2895924817 hasAuthorship W2895924817A5042729624 @default.
• W2895924817 hasAuthorship W2895924817A5053709216 @default.
• W2895924817 hasAuthorship W2895924817A5065451656 @default.
• W2895924817 hasAuthorship W2895924817A5071171991 @default.
• W2895924817 hasAuthorship W2895924817A5072760427 @default.
• W2895924817 hasAuthorship W2895924817A5077820862 @default.
• W2895924817 hasAuthorship W2895924817A5085510763 @default.
• W2895924817 hasAuthorship W2895924817A5085569334 @default.
• W2895924817 hasConcept C121608353 @default.
• W2895924817 hasConcept C126322002 @default.
• W2895924817 hasConcept C126838900 @default.
• W2895924817 hasConcept C2775908122 @default.
• W2895924817 hasConcept C2777416452 @default.
• W2895924817 hasConcept C2777740455 @default.
• W2895924817 hasConcept C2778220009 @default.
• W2895924817 hasConcept C2989005 @default.
• W2895924817 hasConcept C509974204 @default.
• W2895924817 hasConcept C71924100 @default.
• W2895924817 hasConceptScore W2895924817C121608353 @default.
• W2895924817 hasConceptScore W2895924817C126322002 @default.
• W2895924817 hasConceptScore W2895924817C126838900 @default.
• W2895924817 hasConceptScore W2895924817C2775908122 @default.
• W2895924817 hasConceptScore W2895924817C2777416452 @default.
• W2895924817 hasConceptScore W2895924817C2777740455 @default.
• W2895924817 hasConceptScore W2895924817C2778220009 @default.
• W2895924817 hasConceptScore W2895924817C2989005 @default.
• W2895924817 hasConceptScore W2895924817C509974204 @default.
• W2895924817 hasConceptScore W2895924817C71924100 @default.
• W2895924817 hasIssue "3" @default.
• W2895924817 hasLocation W28959248171 @default.
• W2895924817 hasOpenAccess W2895924817 @default.
• W2895924817 hasPrimaryLocation W28959248171 @default.
• W2895924817 hasRelatedWork W2513916013 @default.
• W2895924817 hasRelatedWork W2942848944 @default.
• W2895924817 hasRelatedWork W2966036943 @default.
• W2895924817 hasRelatedWork W3029213237 @default.
• W2895924817 hasRelatedWork W3031343993 @default.
• W2895924817 hasRelatedWork W3104537559 @default.
• W2895924817 hasRelatedWork W4206581437 @default.
• W2895924817 hasRelatedWork W4237106564 @default.
• W2895924817 hasRelatedWork W4313546044 @default.
• W2895924817 hasRelatedWork W4364377845 @default.
• W2895924817 hasVolume "102" @default.
• W2895924817 isParatext "false" @default.
• W2895924817 isRetracted "false" @default.
• W2895924817 magId "2895924817" @default.
• W2895924817 workType "article" @default.